Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022002237 - HPK1 INHIBITORS AND USES THEREOF

Publication Number WO/2022/002237
Publication Date 06.01.2022
International Application No. PCT/CN2021/104206
International Filing Date 02.07.2021
IPC
C07D 401/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
A61K 31/506 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • QILU REGOR THERAPEUTICS INC. [CN]/[CN]
Inventors
  • ZHONG, Wenge
  • ZHU, Xiaotian
  • FENG, Song
  • WU, Lei
  • HUANG, Wei
  • LIU, Hao
  • LIU, Rongqiang
  • WEN, Kate Xin
  • ZHOU, Hua
Agents
  • LIU, SHEN & ASSOCIATES
Priority Data
PCT/CN2020/10013403.07.2020CN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HPK1 INHIBITORS AND USES THEREOF
(FR) INHIBITEURS DE HPK1 ET LEURS UTILISATIONS
Abstract
(EN) The invention provides a compound represented by structural formula (I) or formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.
(FR) L'invention concerne un composé représenté par la formule structurale (I) ou la formule (II), ou un sel pharmaceutiquement acceptable ou un stéréoisomère de celui-ci utile pour le traitement de maladies (notamment le cancer) qui peuvent être traitées par inhibition de l'activité de HPK1.
Latest bibliographic data on file with the International Bureau